Impact of Single-Nucleotide Polymorphisms of CTLA-4, CD80 and CD86 on the Effectiveness of Abatacept in Patients with Rheumatoid Arthritis
- Supplementary File 1:
ZIP-Document (ZIP, 238 KiB)
Marquez Pete, N.; Maldonado Montoro, M.d.M.; Pérez Ramírez, C.; Sánchez Martín, A.; Martínez de la Plata, J.E.; Martínez Martínez, F.; Caliz Caliz, R.; Daddaoua, A.; Ramírez Tortosa, M.d.C.; Jiménez Morales, A. Impact of Single-Nucleotide Polymorphisms of CTLA-4, CD80 and CD86 on the Effectiveness of Abatacept in Patients with Rheumatoid Arthritis. J. Pers. Med. 2020, 10, 220. https://doi.org/10.3390/jpm10040220
Marquez Pete N, Maldonado Montoro MdM, Pérez Ramírez C, Sánchez Martín A, Martínez de la Plata JE, Martínez Martínez F, Caliz Caliz R, Daddaoua A, Ramírez Tortosa MdC, Jiménez Morales A. Impact of Single-Nucleotide Polymorphisms of CTLA-4, CD80 and CD86 on the Effectiveness of Abatacept in Patients with Rheumatoid Arthritis. Journal of Personalized Medicine. 2020; 10(4):220. https://doi.org/10.3390/jpm10040220
Chicago/Turabian StyleMarquez Pete, Noelia, María del Mar Maldonado Montoro, Cristina Pérez Ramírez, Almudena Sánchez Martín, Juan Enrique Martínez de la Plata, Fernando Martínez Martínez, Rafael Caliz Caliz, Abdelali Daddaoua, María del Carmen Ramírez Tortosa, and Alberto Jiménez Morales. 2020. "Impact of Single-Nucleotide Polymorphisms of CTLA-4, CD80 and CD86 on the Effectiveness of Abatacept in Patients with Rheumatoid Arthritis" Journal of Personalized Medicine 10, no. 4: 220. https://doi.org/10.3390/jpm10040220